MYC and prostate carcinoma: Our data demonstrate for the first time that expression levels of all three PIM family kinases can be upregulated during prostate cancer progression and can thereby significantly contribute to this process, especially in cooperation with other co‐overexpressed oncoproteins, such as MYC and ERG, as shown here.